Login to Your Account

Biogen blasts past Q2 expectations with strong MS drug sales

By Michael Fitzhugh
Staff Writer

Wednesday, July 23, 2014
Profits at Biogen Idec Inc. surged in the second quarter on strong sales of Tecfidera (dimethyl fumarate) and its other multiple sclerosis (MS) therapies, beating analyst expectations and pumping up sales forecasts as the company notched a new drug approval in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription